Workflow Evaluation of the Luminex® NxTAG™ Respiratory Pathogen Panel (RUO)

K. Post1, A. Cornwell1, and L. Cheng1

Molecular Laboratory, Department of Pathology and Laboratory Medicine, Indiana University Health, Indianapolis, Indiana

INTRODUCTION

The Luminex® NxTAG™ Respiratory Pathogen Panel (NxTAG RPP) (RUO) is a new multiplexed molecular assay for detection and differentiation of 19 viral and 3 bacterial pathogen nucleic acids from extracted respiratory specimens. After nucleic acid extraction, an aliquot is added directly to pre-plated lyophilized reagents and multiplexed RT-PCR and bead hybridization are carried out in a single thermal cycling program in a closed PCR plate. Upon completion, the plate is transferred to the MAGPIX instrument for reading, data analysis, and results reporting. In this study, we performed a preliminary evaluation of the workflow of NxTAG RPP as compared to our currently used method, the Luminex xTAG® Respiratory Viral Panel (RVPv1).

METHODS

For evaluation of workflow, 24 samples were selected as representative of a typical run size and tested by both methods. Each step of the assay procedure, from sample acquisition to final result, was observed and the data collected include: number of steps, number of manual interventions, hands-on time, and total time.

RESULTS

NxTAG RPP had 6 total fewer steps and 5 fewer manual interventions as compared to RVPv1. The hands-on time was 22 minutes for NxTAG RPP as compared to 1 hour 13 minutes for RVPv1 and the total time for NxTAG RPP as compared to RVPv1 was 3 hours 44 minutes vs. 7 hours 34 minutes, respectively. The steps and time required from sample acquisition to extracted nucleic acid are identical for both assays. However, from PCR set-up to reported result, NxTAG RPP required 6 fewer steps, 51 minutes less hands-on time, and 230 minutes less total time than RVPv1.

CONCLUSIONS

The workflow is significantly improved in NxTAG RPP with only 6 manual steps versus 11 manual steps with the current RVPv1. The hands-on time is reduced from RVPv1 to RPP allowing more batches to be performed and reported in an 8 hours shift. By having RPP results available sooner to clinicians this can greatly decrease the length of stay for patients. Therefore impacting the entire institution where this is implemented.

ACKNOWLEDGEMENTS

Luminex Corporation provided material/product support for this study. Fredrik Skarstedt and Sara Smith from the IU School of Medicine PMEG for their help with the layout of the poster.